List of Myrbetriq drug patents

Myrbetriq is owned by Apgdi.

Myrbetriq contains Mirabegron.

Myrbetriq has a total of 14 drug patents out of which 2 drug patents have expired.

Expired drug patents of Myrbetriq are:

  • US6346532*PED
  • US6346532

Myrbetriq was authorised for market use on 28 June, 2012.

Myrbetriq is available in tablet, extended release;oral dosage forms.

Myrbetriq can be used as administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency, use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency, for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The generics of Myrbetriq are possible to be released after 28 March, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(10 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(4 months ago)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(9 months from now)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(9 months from now)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(9 months from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(1 year, 3 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(1 year, 3 months from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(1 year, 3 months from now)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder
Oct, 2028

(5 years from now)

US8772315

(Pediatric)

APGDI Pharmaceutical composition for treating overactive bladder
Apr, 2029

(6 years from now)

US10842780 APGDI Pharmaceutical composition for modified release
Sep, 2029

(6 years from now)

US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic